Merck has announced the initiation of its global Phase III clinical study of the therapeutic cancer vaccine Stimuvax (BLP25 liposome vaccine, L-BLP25) in patients with advanced, inoperable breast cancer.
The STRIDEa study will determine if the vaccine can extend progression-free survival in patients who are treated with hormonal therapy who have hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Overall survival, quality of life, tumor response and safety will also be assessed in this study.
The study will enrol more than 900 patients with advanced breast cancer at an estimated 180 sites in over 30 countries - within North America, Europe, Asia and Australia; the Principal Investigator is Dr Lawrence Shulman, Chief Medical Officer and Senior VP for Medical Affairs, Dana-Farber Cancer Institute, Boston, US.
Share this: 
Del.icio.us |
Email This | 
Printer Friendly
